KNTPF (Kintor Pharmaceutical) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kintor Pharmaceutical's Revenue for the six months ended in Dec. 2024 was $0.69 Mil. Kintor Pharmaceutical's average Accounts Receivable for the six months ended in Dec. 2024 was $0.00 Mil.

Kintor Pharmaceutical Receivables Turnover Historical Data

The historical data trend for Kintor Pharmaceutical's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Receivables Turnover Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Receivables Turnover	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Kintor Pharmaceutical's Receivables Turnover

For the Biotechnology subindustry, Kintor Pharmaceutical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintor Pharmaceutical's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Kintor Pharmaceutical Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Kintor Pharmaceutical's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0.687	/ (	(0	+	0)	/	1 )
=	0.687	/	0
=	N/A

Kintor Pharmaceutical's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Jun. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0.687	/ (	(0	+	0)	/	1 )
=	0.687	/	0
=	N/A

Kintor Pharmaceutical (OTCPK:KNTPF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Kintor Pharmaceutical Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

09939:Hong Kong

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.